Commercial sponsorship integrates EvE Bio's growing field‑defining "pharmome" map - 385,572 rigorously confirmed drug–target interactions across 159 validated targets - into DrugBank's intelligence ...
Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...
Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally NEW ORLEANS, [November 14, 2024] — In a landmark continuing ...
Korro Bio, Inc. (KRRO) is a biotech that is working on advancing its RNA editing platform OPERA to treat certain types of disorders. The first RNA edited oligonucleotide drug of its kind from this ...
CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced its ...
Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...
Partnership has already generated high-quality, AI-ready data in less than three months MOUNTAIN VIEW, CA / ACCESS Newswire / January 8, 2026 / AbTherx today announced a therapeutic antibody discovery ...
NEW ORLEANS--(BUSINESS WIRE)--In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback